» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
Study aim: The effect of prophylaxis treatment with hydroxychloroquine on the incidence of severe forms of covid-19 virus Design: Randomized controlled trial study; double-blind; parallel groups; on 1000 people; randomization using balanced blocks Settings and conduct: Using balanced blocked randomization people are randomly assigned to one of the two control and intervention groups. The computerization process is done by an epidemiologist and a statistician. For the drug under study, placebo is made by a pharmaceutical company, and participants in the study are blind to receive actual medication. People who measure variables during research are also blind about how people belong to groups. (Two-way blinding) Both intervention and control groups are followed for 10 weeks. Participants/Inclusion and exclusion criteria: Men and women 65-18 years wish to participate in the study have no suspicious symptoms of covid-19 disease Do not have positive test Intervention groups: Intervention Group is500 people and Control Group is 500 people and they are under intervention and follow-up for 10 weeks. Main outcome variables: - COVID-19 Mild type (fever - cough - shortness of breath and positive PCR test) - severe (severe dyspnea - chest pain or constant pressure - decreased level of consciousness - bruising of lips and face and positive PCR test) based on CDC definition
IRCTID: IRCT20200421047153N1
  1. A Field Trial to examine the effect of hydroxychloroquine prophylaxis in preventing the sever forms of COVID-19 infection in asymptomatic healthcare workers (A double blind placebo controlled study)
  2. Evaluation of treatment strategy Included : hydroxychloroquine ,naproxen and oseltamivir for outpatient patients with Covid 19
  3. Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers
  4. The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patients
  5. Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit
  6. Evaluation of the efficacy of N-Acetylcysteine in severe COVID-19 patients: a randomized controlled phase III clinical trial
  7. The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)
  8. Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis
  9. Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease
  10. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study